Reporting and Definition of Kidney Death in Heart Failure Clinical Trials

Bagshaw, 2010, Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI consensus conference, Nephrol Dial Transplant, 25:, 1406, 10.1093/ndt/gfq066 Schefold, 2016, Heart failure and kidney dysfunction: epidemiology, mechanisms and management, Nat Rev Nephrol, 12, 610, 10.1038/nrneph.2016.113 Ronco, 2010, Cardio-renal syndromes: Report from the consensus conference of the acute dialysis quality initiative, Eur Heart J, 31:, 703, 10.1093/eurheartj/ehp507 Ishigami, 2020, Incident hospitalization with major cardiovascular diseases and subsequent risk of ESKD: implications for cardiorenal syndrome, J Am Soc Nephrol, 31, 405, 10.1681/ASN.2019060574 Schrier, 1999, Hormones and hemodynamics in heart failure, N Engl J Med, 341, 577, 10.1056/NEJM199908193410806 Levey, 1998, Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here?, Am J Kidney Dis, 32, 853, 10.1016/S0272-6386(98)70145-3 Wang, 2010, Sudden cardiac death in end-stage renal disease patients: a 5-year prospective analysis, Hypertension, 56, 210, 10.1161/HYPERTENSIONAHA.110.151167 Heerspink, 2020, Dapagliflozin in patients with chronic kidney disease, N Engl J Med, 10.1056/NEJMoa2024816 Perkovic, 2019, Canagliflozin and renal outcomes in type 2 diabetes and nephropathy, N Engl J Med, 380, 2295, 10.1056/NEJMoa1811744 Bakris, 2020, effect of finerenone on chronic kidney disease outcomes in type 2 diabetes, N Engl J Med, 1 Cannon, 2020, Cardiovascular outcomes with ertugliflozin in type 2 diabetes, N Engl J Med, 383, 1425, 10.1056/NEJMoa2004967 Neal, 2017, Canagliflozin and cardiovascular and renal events in type 2 diabetes, N Engl J Med, 377, 644, 10.1056/NEJMoa1611925 Mosenzon, 2019, Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial, Lancet Diabetes Endocrinol, 7, 606, 10.1016/S2213-8587(19)30180-9 Teerlink, 2021, Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure, N Engl J Med, 384, 105, 10.1056/NEJMoa2025797 Solomon, 2019, Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction, N Engl J Med, 381, 1609, 10.1056/NEJMoa1908655 Jhund, 2020, Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of dapa-hf, Circulation Damman, 2014, Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis, Eur Heart J, 35, 455, 10.1093/eurheartj/eht386 Testani, 2010, Characteristics of patients with improvement or worsening in renal function during treatment of acute decompensated heart failure, Am J Cardiol, 106, 1763, 10.1016/j.amjcard.2010.07.050 Packer, 2020, Cardiovascular and renal outcomes with empagliflozin in heart failure, N Engl J Med, 383, 1413, 10.1056/NEJMoa2022190 Bhatt, 2021, Sotagliflozin in patients with diabetes and recent worsening heart failure, N Engl J Med, 384, 117, 10.1056/NEJMoa2030183 Wanner, 2016, Empagliflozin and progression of kidney disease in type 2 diabetes, N Engl J Med, 375, 323, 10.1056/NEJMoa1515920 Rosenstock, 2019, Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the carolina randomized clinical trial, JAMA - J Am Med Assoc, 322, 1155, 10.1001/jama.2019.13772 Solomon, 2019, Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction, N Engl J Med, 381, 1609, 10.1056/NEJMoa1908655 Pecoits-Filho, 2012, Diastolic heart failure in dialysis patients: mechanisms, diagnostic approach, and treatment, Semin Dial, 25, 35, 10.1111/j.1525-139X.2011.01011.x Bellasi, 2006, Correlation of simple imaging tests and coronary artery calcium measured by computed tomography in hemodialysis patients, Kidney Int, 70, 1623, 10.1038/sj.ki.5001820 Herzog, 2008, Sudden cardiac death and dialysis patients, Semin Dial, 21, 300, 10.1111/j.1525-139X.2008.00455.x Thompson, 2015, Cause of death in patients with reduced kidney function, J Am Soc Nephrol, 26, 2504, 10.1681/ASN.2014070714 Webster, 2017, Chronic kidney disease, Lancet, 389, 1238, 10.1016/S0140-6736(16)32064-5 Levin, 2020, International consensus definitions of clinical trial outcomes for kidney failure: 2020, Kidney Int, 98, 849, 10.1016/j.kint.2020.07.013 KDIGO Guidelines. CKD evaluation and management – KDIGO n.d. Available at: https://kdigo.org/guidelines/ckd-evaluation-and-management/. Accessed March 14, 2021. Cooper, 2010, A randomized, controlled trial of early versus late initiation of dialysis, N Engl J Med, 363, 609, 10.1056/NEJMoa1000552